Table 1.
Baseline characteristics
| |
Overall population |
Hypertension |
No hypertension |
|---|---|---|---|
| N = 3078 | N = 817 (27%) | N = 2255 (73%) | |
| Age (years) |
75 (53;89) |
75 (54;89) |
75 (53;89) |
| Male gender* |
61% |
57% |
62% |
| BMI (kg/m2) * |
25.8 (18.7;36.2) |
26.8 (19.3;38.0) |
25.3 (18.5;35.6) |
| Creatinine clearance (mL/min/1.73 m2) |
58 (25;97) |
57 (23;99) |
58 (27;96) |
| Wall motion index * |
1.3 (0.5;2.0) |
1.5 (0.5;2.0) |
1.3 (0.5;2.0) |
| LVEF ≤45% * |
60% |
55% |
62% |
| Smokers |
29% |
29% |
30% |
| Diabetes mellitus * |
15% |
21% |
13% |
| Hyperlipidaemia * |
32% |
36% |
30% |
| History of ischemic heart disease |
44% |
42% |
44% |
| Previous stroke or TIA * |
11% |
15% |
10% |
| Atrial fibrillation |
35% |
35% |
35% |
| COPD |
24% |
23% |
24% |
|
Medications at discharge: |
|
|
|
| Betablockers * |
43% |
51% |
41% |
| ACE inhibitors |
56% |
57% |
55% |
| Angiotensin II blockers * |
7% |
12% |
5% |
| Calcium channel blockers * |
14% |
19% |
12% |
| Diuretics |
93% |
92% |
93% |
| Statins |
18% |
20% |
18% |
| Nitrates |
20% |
19% |
20% |
| Glycosides (digoxin)* |
38% |
34% |
39% |
| Oral anticoagulants* | 30% | 27% | 32% |
Footnote: Continuous variables are presented as median 5th; 95th percentiles.* indicates p for difference between the two sub-groups <0.05.